Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acarix ABFRA:7AC 39 14-Day RSI is 42.48 as of Jul. 16, 2026. GuruFocus rates FRA:7AC with a GF Score™ of 39/100 and a GF Value™ of €0.01. The stock has 1 warning sign investors should review. Among 867 Medical Devices & Instruments companies, Acarix AB ranks better than 75.32% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-07-16), Acarix AB's 14-Day RSI is 42.48.
The industry rank for Acarix AB's 14-Day RSI or its related term are showing as below:
FRA:7AC's 14-Day RSI is ranked better than 75.32% of 867
companies
in the Medical Devices & Instruments industry
Industry Median: 48.54
vs FRA:7AC: 42.48
Acarix AB (FRA:7AC) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
Acarix AB 14-Day RSI Related Terms
FRA:7AC vs ABT, SYK, MDT: 14-Day RSI Comparison
For the Medical Devices subindustry, Acarix AB's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acarix AB 14-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Acarix AB's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where Acarix AB's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acarix AB (FRA:7AC) has a 14-Day RSI of 42.48 as of Jul. 16, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Acarix AB and its competitors. According to the industry distribution chart, Acarix AB ranks #214 out of 867 companies in the Medical Devices & Instruments industry, placing it in the top 24.7%.
Is Acarix AB's 14-Day RSI too high?
Acarix AB's current 14-Day RSI is 42.48. The Medical Devices & Instruments industry median 14-Day RSI is 48.54. Acarix AB's value of 42.48 is 12.5% below this industry median. Based on the distribution chart, Acarix AB ranks #214 out of 867 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Acarix AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Acarix AB's 14-Day RSI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Acarix AB ranks #214 out of 867 companies for 14-Day RSI. This places Acarix AB in the top 25% of its industry — outperforming the majority of peers. The industry median 14-Day RSI is 48.54. Acarix AB's value of 42.48 is 12.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Medical Devices & Instruments company?
The median 14-Day RSI among Medical Devices & Instruments companies is 48.54, based on 867 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acarix AB's current 14-Day RSI of 42.48 is 12.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on Acarix AB and its competitors. For the Medical Devices & Instruments industry, the median 14-Day RSI is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acarix AB's current 14-Day RSI is 42.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acarix AB stock overvalued right now?
Acarix AB (FRA:7AC) has a current 14-Day RSI of 42.48. The stock's GF Value™ is €0.01, compared to a current price of €0.02 — trading 54% above its estimated fair value. The current 14-Day RSI is 42.48 and 12.5% below the Medical Devices & Instruments industry median of 48.54. Acarix AB's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For Acarix AB (FRA:7AC), the current 14-Day RSI is 42.48 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acarix AB (FRA:7AC) Overvalued in 2026?
Based on GuruFocus' analysis, Acarix AB stock appears to be overvalued.
The current stock price of €0.02 is trading 54% above its estimated GF Value™ of €0.01.
Key valuation signals for FRA:7AC:
14-Day RSI: 42.48
GF Value™: €0.01 vs. price of €0.02 (54% above fair value)
Industry Position: 12.5% below the Medical Devices & Instruments median (#214 of 867)
No single metric tells the full story. See the FRA:7AC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acarix AB is a Swedish medical technology company that develops solutions for rapid AI-based exclusion of coronary artery disease (CAD). Its CE-marked CADScor System, which has also received DeNovo approval from the FDA, is intended for patients experiencing chest pain with suspected coronary artery disease and is designed to help reduce millions of cases of unnecessary, invasive, and costly diagnostics. Acarix recommends the CADScor System as a first-line diagnostic tool that uses sensitive acoustics and computational processing to analyze coronary blood flow to rule out coronary artery disease (CAD), with a majority certainty at the point of care. Geographically, the company generates maximum revenue from the United States, and the rest from Germany, Sweden, Iraq, and other regions.
39GF Score
Get the complete analysis for FRA:7AC
14-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AC has been successfully added to your 
